Nevertheless, the use of CD27 agonists synergized with PD-1 blockade, by boosting cytotoxic CD8+ T cell-based anti-tumor immunity emphasizing the potential of combinatorial agonistic and antagonistic therapeutical approaches [481]. This evidence concerns the gene CD8A and neoplasm.